Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars, what the regulatory issues are, and bringing a biobetter to market.
A core aspect of the drug development landscape has been and always will be an intimate expertise in therapeutic areas. Our experts will partner with…
PRA Insights Report 2017
The theme for this year’s DIA 2017 Annual Meeting was “Driving Insights to Action.” DIA hosted more than 7,000 professionals in the pharmaceutical,…
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.